Elevation of arachidonoylethanolamide levels by activation of the endocannabinoid system protects against colitis and ameliorates remote organ lesions in mice.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Experimental and Therapeutic Medicine

• Publication date

  2017-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/etm.2017.5222PMID 29285108PMCID PMC5740744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endocannabinoid Degradation Inhibition Improves Neurobehavioral Function, Blood–Brain Barrier Integrity, and Neuroinflammation following Mild Traumatic Brain Injury

  2015cited by this paper
• Therapeutic Potential of Inhibitors of Endocannabinoid Degradation for the Treatment of Stress-Related Hyperalgesia in an Animal Model of Chronic Pain

  2015cited by this paper
• Preview : Published ahead of advance online publication Therapeutic Potential of Inhibitors of Endocannabinoid Degradation for the Treatment of Stress-Related Hyperalgesia in an Animal Model of Chronic Pain

  2014cited by this paper
• Experimental Cannabinoid 2 Receptor-Mediated Immune Modulation in Sepsis

  2014cited by this paper
• Functions of the CB1 and CB2 Receptors in Neuroprotection at the Level of the Blood–Brain Barrier

  2014cited by this paper
• Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not “higher”

  2014influential reference
• Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation‐induced cognitive damage

  2014cited by this paper
• Contextual and Cued Fear Conditioning Test Using a Video Analyzing System in Mice

  2014cited by this paper
• FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus.

  2014cited by this paper
• Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease

  2013cited by this paper
• The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.

  2012influential reference
• Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities

  2012cited by this paper
• Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors*

  2012cited by this paper
• The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation

  2012cited by this paper
• Gut feelings about the endocannabinoid system

  2011influential reference
• Cannabinoids and Innate Immunity: Taking a Toll on Neuroinflammation

  2011cited by this paper
• Increasing endogenous 2‐arachidonoylglycerol levels counteracts colitis and related systemic inflammation

  2011influential reference
• Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.

  2010cited by this paper
• Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.

  2010cited by this paper
• Cannabinoids and the gut: new developments and emerging concepts.

  2010influential reference
• The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.

  2009cited by this paper
• Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors

  2008cited by this paper
• Mouse models of inflammatory bowel disease.

  2007cited by this paper
• The endocannabinoid system and its therapeutic exploitation

  2004cited by this paper
• Endocannabinoid degradation, endotoxic shock and inflammation.

  2002cited by this paper
• The endocannabinoid system as a target for therapeutic drugs.

  2000cited by this paper

• The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update

  2024cites this paper
• Psychiatric Comorbidities of Inflammatory Bowel Disease: It Is a Matter of Microglia’s Gut Feeling

  2024cites this paper
• The Gut–Immune–Brain Axis: An Important Route for Neuropsychiatric Morbidity in Inflammatory Bowel Disease

  2022cites this paper
• The synthetic CB1 cannabinoid receptor selective agonists: Putative medical uses and their legalization.

  2021cites this paper
• Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase

  2021cites this paper
• Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation

  2021cites this paper
• Endocannabinoids Inhibit the Induction of Virulence in Enteric Pathogens.

  2020cites this paper
• Functional Lipids in Autoimmune Inflammatory Diseases

  2020cites this paper
• Medical Cannabis and Cannabinoids: An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon?

  2018cites this paper
• Cannabis, Cannabinoids, and the Endocannabinoid System—Is there Therapeutic Potential for Inflammatory Bowel Disease?

  2018cites this paper